/IRLAB-A.ST
IRLAB-A.ST Stock - IRLAB Therapeutics AB (publ)
Healthcare|BiotechnologySTO
$1.97+4.57%
+$0.09 (+4.57%) • Dec 23
54
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.96
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.16
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IRLAB-A.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.95 – $1.99
TARGET (TP)$2.26
STOP LOSS$1.81
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.60
52W High$16.50
52W Low$1.80
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $94.63M | $5.68M | $61.14M | $207.78M | $300,000 |
| Gross Profit | $-92,423,000 | $-122,734,000 | $-111,233,000 | $168.69M | $-1,697,000 |
| Gross Margin | -97.7% | -2161.6% | -181.9% | 81.2% | -565.7% |
| Operating Income | $-75,111,000 | $-180,765,000 | $-113,109,000 | $52.58M | $-91,458,000 |
| Net Income | $-83,129,000 | $-177,839,000 | $-114,203,000 | $51.78M | $-91,848,000 |
| Net Margin | -87.8% | -3132.1% | -186.8% | 24.9% | -30616.0% |
| EPS | $-1.60 | $-3.43 | $-2.20 | $1.00 | $-1.93 |
Company Overview
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
IRLAB-A.STBeat Rate
100%
Last 4 quarters
Avg Surprise
+40.0%
EPS vs Estimate
Beats / Misses
4/0
Last 12 quarters
Latest EPS
$-0.24
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | — | — | — | — |
Q4 2025 | Oct 29, 2025 | — | $-0.24 | — | — |
Q3 2025 | Aug 27, 2025 | — | $-0.62 | — | — |
Q2 2025 | May 7, 2025 | — | $-0.65 | — | — |
Q1 2025 | Feb 14, 2025 | — | $-0.10 | — | — |
Q4 2024 | Oct 30, 2024 | — | $-0.61 | — | — |
Q3 2024 | Jul 10, 2024 | — | $-0.14 | — | — |
Q2 2024 | May 8, 2024 | — | $-0.75 | — | — |
Q1 2024 | Feb 7, 2024 | — | $-0.67 | — | — |
Q4 2023 | Oct 25, 2023 | — | $-0.74 | — | — |
Q3 2023 | Aug 30, 2023 | — | $-0.87 | — | — |
Q2 2023 | May 10, 2023 | — | $-1.15 | — | — |
Q1 2023 | Feb 23, 2023 | $-1.19 | $-0.64 | +46.2% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-1.09 | $-0.46 | +57.8% | ✓ BEAT |
Q3 2022 | Aug 24, 2022 | $-0.90 | $-0.52 | +42.2% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.65 | $-0.56 | +13.8% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | — | $-0.45 | — | — |
Q4 2021 | Nov 10, 2021 | — | $2.35 | — | — |
Q3 2021 | Aug 25, 2021 | — | $-0.51 | — | — |
Latest News
Loading news...
Frequently Asked Questions about IRLAB-A.ST
What is IRLAB-A.ST's current stock price?
IRLAB Therapeutics AB (publ) (IRLAB-A.ST) is currently trading at $1.97 per share. The stock has moved +4.57% today.
What is the analyst price target for IRLAB-A.ST?
No analyst price targets are currently available for this stock.
What sector is IRLAB Therapeutics AB (publ) in?
IRLAB Therapeutics AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is IRLAB-A.ST's market cap?
IRLAB Therapeutics AB (publ) has a market capitalization of $0.17 billion, making it a small-cap company.
Does IRLAB-A.ST pay dividends?
No, IRLAB Therapeutics AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACTI.ST
Active Biotech AB (publ)
$0.04
Mkt Cap: $0.1B
ALZ.ST
Alzinova AB (publ)
$0.82
Mkt Cap: $0.1B
ANNX.ST
Annexin Pharmaceuticals AB (publ)
$19.00
Mkt Cap: $0.1B
BIOWKS.ST
Bio-Works Technologies AB (publ)
$2.25
Mkt Cap: $0.2B
CLS-B.ST
Clinical Laserthermia Systems AB (publ)
$7.00
Mkt Cap: $0.2B
INIT.ST
Initiator Pharma A/S
$2.93
Mkt Cap: $0.2B
ISOFOL.ST
Isofol Medical AB (publ)
$0.72
Mkt Cap: $0.2B
KDEV.ST
Karolinska Development AB (publ)
$0.43
Mkt Cap: $0.1B
LIPUM.ST
Lipum AB (publ)
$14.55
Mkt Cap: $0.3B
XBRANE.ST
Xbrane Biopharma AB (publ)
$10.88
Mkt Cap: $0.1B
Explore stocks similar to IRLAB-A.ST for comparison